Snapshot from Jul 23, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Business / PharmAla ALA-002 Manufacturing,...
Business drug development

PharmAla ALA-002 Manufacturing, Patent, Australia

Analysis based on 8 articles · First reported Jul 06, 2026 · Last updated Jul 06, 2026

Sentiment
70
Attention
4
Articles
8
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The successful GMP manufacturing and patent grant for Non-racemic MDMA by PharmAla Biotech Holdings are positive developments for the biotechnology sector, particularly for companies involved in psychedelic-based therapies. The commercialization agreement with Cortexa for the Australian market indicates potential revenue streams and market expansion, which could positively impact PharmAla Biotech Holdings's stock price and investor confidence in the long term.

biotechnology pharmaceuticals
Event Summary

PharmAla Biotech Holdings announced the successful completion of GMP manufacturing for the drug substance of its lead candidate, Non-racemic MDMA, providing material for upcoming clinical activities. The company also secured an Australian patent for Non-racemic MDMA. Furthermore, Cortexa, a joint venture involving PharmAla Biotech Holdings and Vitura Health, exercised its option to commercialize Non-racemic MDMA in Australia, where it will be branded as LaNeo Gen 2. These milestones are crucial for advancing Non-racemic MDMA towards clinical trials and commercialization, particularly in the Australian market.

Key Actions
95 PharmAla Biotech Holdings completed manufacturing Non-racemic MDMA
85 PharmAla Biotech Holdings granted patent Australia
80 Cortexa exercised option Non-racemic MDMA
75 PharmAla Biotech Holdings branded drug product Non-racemic MDMA
Entities Involved
stock
PharmAla Biotech Holdings
PharmAla Biotech Holdings successfully completed GMP manufacturing of drug substance for Non-racemic MDMA, was granted an Australian patent for Non-racemic MDMA, and will brand Non-racemic MDMA as LaNeo Gen 2 in Australia. These advancements position the company for upcoming clinical activities and commercialization.
Importance 100.0 Sentiment 75.0
oth
Non-racemic MDMA
Non-racemic MDMA is PharmAla Biotech Holdings's lead drug candidate, for which GMP manufacturing of drug substance is complete, an Australian patent has been granted, and commercialization rights in Australia have been exercised by Cortexa.
Importance 90.0 Sentiment 70.0
priv
Cortexa
Cortexa, a joint venture between PharmAla Biotech Holdings and Vitura Health, exercised its option to commercialize Non-racemic MDMA intellectual property for the Australian market, where it holds a dominant position.
Importance 70.0 Sentiment 60.0
cnt
Australia
Australia is the territory where PharmAla Biotech Holdings was granted a patent for Non-racemic MDMA and where Cortexa will commercialize the drug product under the LaNeo Gen 2 brand.
Importance 50.0 Sentiment 0.0
stock
Vitura Health
Vitura Health is a partner in the Cortexa joint venture, which exercised its option to commercialize Non-racemic MDMA in Australia.
Importance 30.0 Sentiment 50.0
per
Farnoud Kazemzadeh
Farnoud Kazemzadeh, COO of PharmAla Biotech Holdings, commented on the significance of the GMP manufacturing milestone for Non-racemic MDMA.
Importance 20.0 Sentiment 0.0
per
Nick Kadysh
Nick Kadysh, CEO of PharmAla Biotech Holdings, highlighted the importance of the LaNeo branding for Non-racemic MDMA's commercial utilization in Australia.
Importance 20.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.